Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gary Barnette Insider Profile
4 Followers
Gary Barnette, VP at Oncternal Therapeutics, holds 0.00 shares in Oncternal Therapeutics (Ticker: ONCT), holds 5.00K shares in Veru (Ticker: VERU). Most recently, Gary Barnette ― shares of Oncternal Therapeutics on ― for an estimated value of ―.
Profitable Transactions
2 out of 3 Profitable Transactions
Average Return
+33.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by Gary Barnette
Gary Barnette's Trading History
Oncternal Therapeutics
―
VP
―
$0.00
Veru
May 24, 2024
CSO
Informative Buy
6.65K
$4.32K
List of latest transactions for each holding click on a transaction to see Gary Barnette's performance on stock
You May Also Like
Gary Barnette insider profile FAQ
What is the percentage of profitable transactions made by Gary Barnette?
The percentage of profitable transactions made by Gary Barnette is 67%.
What is the average return per transaction made by Gary Barnette?
The average return per transaction made by Gary Barnette is 33.20%.
What stocks does Gary Barnette hold?
Gary Barnette holds: ONCT, VERU stocks.
What was Gary Barnette’s latest transaction?
Gary Barnette latest transaction was an Uninformative Buy of ―.
What was Gary Barnette's most profitable transaction?
Gary Barnette’s most profitable transaction was an Informative Buy of VERU stock on December 19, 2018. The return on the trade was 104.40%.
What is Gary Barnette's role in Oncternal Therapeutics?
Gary Barnette's role in Oncternal Therapeutics is VP.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.